
OR WAIT null SECS
© 2025 MJH Life Sciences™ and Pharmaceutical Commerce - Biopharma Business News, Market Insights. All rights reserved.
This episode of Pharma Pulse discusses how the FDA’s new plausible mechanism pathway, WeightWatchers’ plans to offer oral Wegovy, and emerging evidence on berberine are shaping the future of obesity and metabolic health care.
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and in today’s headlines, the FDA introduces a new plausible mechanism pathway for drug approval, WeightWatchers intends to offer Novo Nordisk’s oral Wegovy, and berberine emerges as treatment for metabolic syndrome.
Together, these stories underscore a pivotal trend—innovation across both regulatory and therapeutic fronts is accelerating access to metabolic and chronic disease care, blending science, technology, and patient-centric delivery models.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.
Related Content: